Literature DB >> 31329378

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.

Mmakgomo M Raesima1, Chibuike M Ogbuabo2, Vasavi Thomas3, Sara E Forhan4, Gadzikanani Gokatweng2, Eldah Dintwa1, Chipo Petlo1, Catherine Motswere-Chirwa5, Elizabeth M Rabold4, Sarah C Tinker4, Shifawu Odunsi6, Sifelani Malima1, Omphemetse Mmunyane1, Thusoetsile Modise1, Kelame Kefitlhile1, Kunle Dare5, Mpho Letebele5, Michelle E Roland5, Cynthia A Moore4, Surbhi Modi4, Dhelia M Williamson4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31329378      PMCID： PMC6713595          DOI： 10.1056/NEJMc1908155

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected.

Authors:  Claudia S Crowell; Paige L Williams; Cenk Yildirim; Russell B Van Dyke; Renee Smith; Ellen G Chadwick; George R Seage; Alexandria Diperna; Rohan Hazra
Journal:  AIDS       Date:  2020-07-15       Impact factor: 4.177

2.  Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.

Authors:  Matthew L Romo; Rena C Patel; Jessie K Edwards; John M Humphrey; Beverly S Musick; Caitlin Bernard; Mercy W Maina; Ellen Brazier; Barbara Castelnuovo; Jeremy Penner; Katarzyna Wyka; Sandra Wagner Cardoso; Penh Sun Ly; Cordelia Kunzekwenyika; Claudia P Cortés; Radoslaw Panczak; Elizabeth A Kelvin; Kara K Wools-Kaloustian; Denis Nash
Journal:  Ann Intern Med       Date:  2021-11-30       Impact factor: 51.598

Review 3.  A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.

Authors:  Alexa Vyain Zhao; Rustin D Crutchley; Rakesh Chowdary Guduru; Kathy Ton; Tammie Lam; Amy Cheng Min
Journal:  Retrovirology       Date:  2022-10-22       Impact factor: 3.768

4.  Limited surface examination to evaluate potential teratogens in a resource-limited setting.

Authors:  Lewis B Holmes; Hanah Z Nasri; Anne-Therese Hunt; Rebecca Zash; Roger L Shapiro
Journal:  Birth Defects Res       Date:  2021-03-28       Impact factor: 2.344

5.  Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.

Authors:  Steve Kanters; Marco Vitoria; Michael Zoratti; Meg Doherty; Martina Penazzato; Ajay Rangaraj; Nathan Ford; Kristian Thorlund; Prof Aslam H Anis; Mohammad Ehsanul Karim; Lynne Mofenson; Rebecca Zash; Alexandra Calmy; Tamara Kredo; Nick Bansback
Journal:  EClinicalMedicine       Date:  2020-10-16

6.  Weight gain during pregnancy among women initiating dolutegravir in Botswana.

Authors:  Ellen C Caniglia; Roger Shapiro; Modiegi Diseko; Blair J Wylie; Chloe Zera; Sonya Davey; Arielle Isaacson; Gloria Mayondi; Judith Mabuta; Rebecca Luckett; Joseph Makhema; Mompati Mmalane; Shahin Lockman; Rebecca Zash
Journal:  EClinicalMedicine       Date:  2020-11-05

7.  Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.

Authors:  Gerson Fernando Mendes Pereira; Ahra Kim; Emilia M Jalil; Fernanda Fernandes Fonseca; Bryan E Shepherd; Valdilea G Veloso; Fernanda Rick; Rachel Ribeiro; Maria Cristina Pimenta; Andrea Beber; Renato Girade Corrêa; Renato Lima; Fernanda Maruri; Catherine C McGowan; Adele Schwartz Benzaken; Beatriz Grinsztejn; Jessica L Castilho
Journal:  Lancet HIV       Date:  2021-01       Impact factor: 12.767

Review 8.  Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review.

Authors:  Sonia Menon; Lenka Benova; Hillary Mabeya
Journal:  BMC Med       Date:  2020-11-17       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.